Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

Autor: Giovanni Cazzaniga, Paola De Lorenzo, Julia Alten, Silja Röttgers, Jeremy Hancock, Vaskar Saha, Anders Castor, Hans O. Madsen, Virginie Gandemer, Hélène Cavé, Veronica Leoni, Rolf Köhler, Giulia M. Ferrari, Kirsten Bleckmann, Rob Pieters, Vincent van der Velden, Jan Stary, Jan Zuna, Gabriele Escherich, Udo zur Stadt, Maurizio Aricò, Valentino Conter, Martin Schrappe, Maria Grazia Valsecchi, Andrea Biondi

Publikováno v: Haematologica, Vol 103, Iss 1 (2018)

The prognostic value of minimal residual disease (MRD) in Philadelphia-chromosome-positive (Ph+) childhood acute lymphoblastic leukemia (ALL) treated with tyrosine kinase inhibitors is not fully established. We detected MRD by real-time quantitative

Externí odkaz: https://doaj.org/article/30f38c1156f84e1d923808681a05a34f

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

Autor: Virginie Gandemer, Kirsten Bleckmann, Giovanni Cazzaniga, Anders Castor, Martin Schrappe, Rob Pieters, Andrea Biondi, Maria Grazia Valsecchi, Giulia Maria Ferrari, Valentino Conter, Hélène Cavé, Maurizio Aricò, Hans O. Madsen, Jan Stary, Silja Röttgers, Veronica Leoni, Vincent H.J. van der Velden, Rolf Köhler, Udo zur Stadt, Jan Zuna, Paola De Lorenzo, Vaskar Saha, Gabriele Escherich, Jeremy Hancock, Julia Alten

Publikováno v: Haematologica
Cazzaniga, G, De Lorenzo, P, Alten, J, Röttgers, S, Hancock, J, Saha, V, Castor, A, Madsen, H O, Gandemer, V, Cavé, H, Leoni, V, Köhler, R, Ferrari, G M, Bleckmann, K, Pieters, R, van der Velden, V, Stary, J, Zuna, J, Escherich, G, Stadt, U Z, Aricò, M, Conter, V, Schrappe, M, Valsecchi, M G & Biondi, A 2018, ' Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies ', Haematologica, vol. 103, no. 1, pp. 107-115 . https://doi.org/10.3324/haematol.2017.176917
Haematologica, 103(1), 107-115. Ferrata Storti Foundation

The prognostic value of minimal residual disease (MRD) in Philadelphia-chromosome-positive (Ph+) childhood acute lymphoblastic leukemia (ALL) treated with tyrosine kinase inhibitors is not fully established. We detected MRD by real-time quantitative

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bb63ad90c3991b9b3c794d6e2870446
https://pure.eur.nl/en/publications/682165d6-bf16-4188-a748-876de7951c83

Osteonecrosis develops independently from radiological leukemic infiltration of bone in adolescents with acute lymphoblastic leukemia – first findings of the OPAL trial

Autor: Dirk Klee, Kirsten Bleckmann, Marina Kunstreich, Andreas Kloetgen, Arndt Borkhardt, Franziska Gruener, R Kolb, Daniel Steinbach, Gabriele Escherich, Janina Klasen-Sansone, Anja Moericke, Carl Friedrich Classen, Andreas Guggemos, Martin Schrappe, Norbert Jorch, Michaela Kuhlen, Kathinka Krull

Publikováno v: Leukemia & Lymphoma. 58:2363-2369

Osteonecrosis (ON) is a debilitating side effect of anti-leukemic treatment. Thus far, the role of leukemic infiltration (LI) of bone is unclear. The first 30 children aged ≥10 years, who were enrolled in the ongoing OPAL trial and had MRI studies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6cfc47ea648a913c28bce2812bb0fd5
https://doi.org/10.1080/10428194.2017.1280605

T-cell acute lymphoblastic leukemia in infants has distinct genetic and epigenetic features compared to childhood cases

Autor: Arndt Borkhardt, Mareike Doerrenberg, Alice C. McHardy, Martin Schrappe, Andreas Kloetgen, Wilhelm Wössmann, Jessica I. Hoell, Kebria Hezaveh, Martin Stanulla, Kirsten Bleckmann

Publikováno v: Genes, Chromosomes and Cancer. 56:159-167

For reasons not yet understood, nearly all infants with acute lymphoblastic leukemia (ALL) are diagnosed with the B-cell type, with T-ALL in infancy representing a very rare exception. Clinical and molecular knowledge about infant T-ALL is still near

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2c90b71899f523286eec4f7076a7b844
https://doi.org/10.1002/gcc.22423

High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6-RUNX1-positive acute lymphoblastic leukemia

Autor: Helia Pimentel Gutiérrez, Martin A. Horstmann, Jana Hoffmann, Cornelia Eckert, Rolf Köhler, Manuela Krumbholz, Udo zur Stadt, Marion Fillies, Arend von Stackelberg, Annabell Szymansky, Roland P. Kuiper, Markus Metzler, Kirsten Bleckmann

Publikováno v: Pediatric Blood & Cancer, 66, 8, pp. e27780
Pediatric Blood & Cancer, 66, e27780

Contains fulltext : 207610.pdf (Publisher’s version ) (Closed access) BACKGROUND: Assessment of minimal residual disease (MRD) is an integral component for response monitoring and treatment stratification in acute lymphoblastic leukemia (ALL). We a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6041a0e542417bcfb13bf7bae8c454fa
https://pubmed.ncbi.nlm.nih.gov/31034759